Latest Publications

@article{kahounova_circulating_2023,

title = {Circulating tumor cell-derived preclinical models: current status and future perspectives.},

author = {Zuzana Kahounová and Markéta Pícková and Stanislav Drápela and Jan Bouchal and Eva Szczyrbová and Jiří Navrátil and Karel Souček},

doi = {10.1038/s41419-023-06059-6},

issn = {2041-4889},

year  = {2023},

date = {2023-08-01},

journal = {Cell death & disease},

volume = {14},

number = {8},

pages = {530},

abstract = {Despite the advancements made in the diagnosis and treatment of cancer, the stages associated with metastasis remain largely incurable and represent the primary cause of cancer-related deaths. The dissemination of cancer is facilitated by circulating tumor cells (CTCs), which originate from the primary tumor or metastatic sites and enter the bloodstream, subsequently spreading to distant parts of the body. CTCs have garnered significant attention in research due to their accessibility in peripheral blood, despite their low abundance. They are being extensively studied to gain a deeper understanding of the mechanisms underlying cancer dissemination and to identify effective therapeutic strategies for advanced stages of the disease. Therefore, substantial efforts have been directed towards establishing and characterizing relevant experimental models derived from CTCs, aiming to provide relevant tools for research. In this review, we provide an overview of recent progress in the establishment of preclinical CTC-derived models, such as CTC-derived xenografts (CDX) and cell cultures, which show promise for the study of CTCs. We discuss the advantages and limitations of these models and conclude by summarizing the potential future use of CTCs and CTC-derived models in cancer treatment decisions and their utility as precision medicine tools.},

note = {Place: England},

keywords = {*Neoplastic Cells, Cell Culture Techniques, Circulating, Heterografts, Heterologous, Humans, Precision Medicine, Transplantation},

pubstate = {published},

tppubtype = {article}

}

@article{slabakova_opposite_2015,

title = {Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.},

author = {Eva Slabáková and Gvantsa Kharaishvili and Monika Smějová and Zuzana Pernicová and Tereza Suchánková and Ján Remšík and Stanislav Lerch and Nicol Straková and Jan Bouchal and Milan Král and Zoran Culig and Alois Kozubík and Karel Souček},

doi = {10.18632/oncotarget.5392},

issn = {1949-2553},

year  = {2015},

date = {2015-11-01},

journal = {Oncotarget},

volume = {6},

number = {34},

pages = {36156–36171},

abstract = {Plasticity of cancer cells, manifested by transitions between epithelial and mesenchymal phenotypes, represents a challenging issue in the treatment of neoplasias. Both epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are implicated in the processes of metastasis formation and acquisition of stem cell-like properties. Mouse double minute (MDM) 2 and MDMX are important players in cancer progression, as they act as regulators of p53, but their function in EMT and metastasis may be contradictory. Here, we show that the EMT phenotype in multiple cellular models and in clinical prostate and breast cancer samples is associated with a decrease in MDM2 and increase in MDMX expression. Modulation of EMT-accompanying changes in MDM2 expression in benign and transformed prostate epithelial cells influences their migration capacity and sensitivity to docetaxel. Analysis of putative mechanisms of MDM2 expression control demonstrates that in the context of defective p53 function, MDM2 expression is regulated by EMT-inducing transcription factors Slug and Twist. These results provide an alternative context-specific role of MDM2 in EMT, cell migration, metastasis, and therapy resistance.},

note = {Place: United States},

keywords = {Animals, Breast Neoplasms/genetics/*metabolism/pathology, Cell Cycle Proteins, Cell Line, Epithelial-Mesenchymal Transition, Epithelial-Mesenchymal Transition/*physiology, Female, Heterografts, Humans, Male, MDM2/MDMX, Mice, Nuclear Proteins/*biosynthesis, Nude, Phenotype, prostate/breast cancer, Prostatic Neoplasms/genetics/*metabolism/pathology, Proto-Oncogene Proteins c-mdm2/*biosynthesis, Proto-Oncogene Proteins/*biosynthesis, Snai2/Slug, Transfection, Tumor, TWIST},

pubstate = {published},

tppubtype = {article}

}

@article{kratochvilova_tumor_2015,

title = {Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.},

author = {Kateřina Kratochvílová and Peter Horak and Milan Ešner and Karel Souček and Dietmar Pils and Mariam Anees and Erwin Tomasich and František Dráfi and Veronika Jurtíková and Aleš Hampl and Michael Krainer and Petr Vaňhara},

doi = {10.1002/ijc.29502},

issn = {1097-0215 0020-7136},

year  = {2015},

date = {2015-09-01},

journal = {International journal of cancer},

volume = {137},

number = {6},

pages = {1330–1340},

abstract = {Ovarian cancer is one of the most common malignancies in women and contributes greatly to cancer-related deaths. Tumor suppressor candidate 3 (TUSC3) is a putative tumor suppressor gene located at chromosomal region 8p22, which is often lost in epithelial cancers. Epigenetic silencing of TUSC3 has been associated with poor prognosis, and hypermethylation of its promoter provides an independent biomarker of overall and disease-free survival in ovarian cancer patients. TUSC3 is localized to the endoplasmic reticulum in an oligosaccharyl tranferase complex responsible for the N-glycosylation of proteins. However, the precise molecular role of TUSC3 in ovarian cancer remains unclear. In this study, we establish TUSC3 as a novel ovarian cancer tumor suppressor using a xenograft mouse model and demonstrate that loss of TUSC3 alters the molecular response to endoplasmic reticulum stress and induces hallmarks of the epithelial-to-mesenchymal transition in ovarian cancer cells. In summary, we have confirmed the tumor-suppressive function of TUSC3 and identified the possible mechanism driving TUSC3-deficient ovarian cancer cells toward a malignant phenotype.},

note = {Place: United States},

keywords = {Animals, Cell Line, Endoplasmic Reticulum Stress, Endoplasmic Reticulum Stress/*genetics, Epithelial-Mesenchymal Transition/*genetics, epithelial-to-mesenchymal transition, Female, Genes, Heterografts, Humans, Inbred NOD, Membrane Proteins/*genetics, Mice, N33, ovarian cancer, Ovarian Neoplasms/*genetics, SCID, Tumor, Tumor Suppressor, Tumor Suppressor Proteins/*genetics, Tumor Suppressor/physiology, TUSC3},

pubstate = {published},

tppubtype = {article}

}